Pulmonary Disease & Injury

An unmet need for effective treatments for pulmonary diseases represents a large burden on medical practice.  The initiation and progression processes are not fully understood for many pulmonary diseases. The prevalence of Obstructive Lung Disease (COPD, Airway Hyper-Reactivity), Restrictive Lung Disease (Pulmonary Fibrosis) and Pulmonary Arterial Hypertension (PAH) is increasing every year due to a multitude of factors as well as increased precision in diagnosis. PBI is a leader in pulmonary therapeutic development, offering an expanding portfolio of pulmonary disease models ranging from acute injury to fibrotic disease. In accordance with our integrative platform, concomitant right side heart remodeling and pulmonary hemodynamics are regularly evaluated to provide interpretable data to best represent human disease.

Pulmonary Fibrosis

Pulmonary Arterial Hypertension

Acute Lung Injury

Airway Hyper-Responsiveness (AHR) / Asthma